Share this article
Share this article
HOUSTON, May 25, 2021 /PRNewswire/ AuraVax Therapeutics, Inc. (Auravax), a biotech company developing novel intranasal therapeutics and vaccines to help patients defeat debilitating respiratory diseases, including COVID-19, today announced the formation of its inaugural Scientific Advisory Board (SAB), consisting of leading experts in the fields of biology, vaccines and intranasal drug delivery. The SAB will guide and advise the company in its ongoing development of proprietary therapeutics and vaccines for respiratory diseases.
The SAB is chaired by George M. Church, Ph.D. and includes Stephen Albert Johnston from Calviri, Inc and Mei X. Wu, Ph.D. from Massachusetts General Hospital/Harvard Medical School.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Calviri Appoints Marc Wolff Chief Executive Officer
April 12, 2021 GMT
Calviri Appoints Marc Wolff Chief Executive Office (Photo: Business Wire).
PHOENIX (BUSINESS WIRE) Apr 12, 2021
Calviri announces the appointment of Marc Wolff as Chief Executive Officer. Founder and current CEO, Stephen Albert Johnston, will continue to serve as Chairman of the Board of Directors and Founding CEO.
ADVERTISEMENT
Calviri Appoints Marc Wolff Chief Executive Office (Photo: Business Wire).
“We are thrilled to welcome Marc Wolff to Calviri as we progress to commercialization. Marc’s successful life science and healthcare management experience, in both public and private corporations, makes him an excellent individual to lead the company toward significant growth objectives,” said Johnston, Founding CEO. “We were impressed as we watched his accomplishments at Aldevron and were elated we were ab